Wave Life Sciences Ltd. (WVE)
NASDAQ: WVE · Real-Time Price · USD
13.00
-0.12 (-0.91%)
Mar 9, 2026, 1:55 PM EDT - Market open
Wave Life Sciences Employees
Wave Life Sciences had 317 employees as of December 31, 2025. The number of employees increased by 29 or 10.07% compared to the previous year.
Employees
317
Change (1Y)
29
Growth (1Y)
10.07%
Revenue / Employee
$134,785
Profits / Employee
-$644,726
Market Cap
2.45B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Telix Pharmaceuticals | 1,184 |
| Apellis Pharmaceuticals | 739 |
| Adaptive Biotechnologies | 624 |
| Beam Therapeutics | 511 |
| Travere Therapeutics | 497 |
| Ocular Therapeutix | 325 |
| Dyne Therapeutics | 258 |
| Day One Biopharmaceuticals | 178 |
WVE News
- 3 days ago - FDA reversals leave investors worrying about the fates of other experimental drugs - CNBC
- 4 days ago - Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference - GlobeNewsWire
- 10 days ago - Wave Life Sciences Ltd. (WVE) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 14 days ago - Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 18 days ago - Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026 - GlobeNewsWire
- 4 weeks ago - Wave Life Sciences Reclaims Rare Disease Drug From GSK, Targets Faster FDA Path - Benzinga
- 5 weeks ago - Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency - GlobeNewsWire